MindRank is an artificial intelligence (AI)-empowered drug discovery company. It has three proprietary technology platforms – end-to-end drug design platform Molecule Pro™️, molecular dynamics platform Molecule Dance™️ , and biomedical knowledge graph PharmKG™️. By leveraging its proprietary AI platforms, the company aims to significantly accelerate the drug discovery process and deliver small molecule medicines with differentiations and clinical benefits.
MindRank’s first AI-designed proprietary small molecule GLP-1RA MDR-001 received FDA T2D and obesity IND approval in 19 months since program initiation, now in Phase II clinical development. The company has been named as one of the "100 to Watch" in Forbes Asia's 2023 list.